Jul. 31 at 5:11 PM
$NRXP While the management’s execution has often been criticized, one achievement deserves credit: securing the ANDA for NRX-100. Currently, most FDA-approved ketamine products for anesthesia and pain management contain preservatives that can cause side effects. The few preservative-free alternatives either have limited shelf life or lack insurance coverage.
If NRX-100’s ANDA is approved, it can be marketed as a preservative-free generic ketamine with longer shelf life and insurance coverage—offering a distinct competitive edge in a U.S. market valued at
$750M. Capturing just 20% of this market could generate
$150M in annual revenue. At a conservative 4× revenue multiple, this implies a
$600M valuation—approximately 12× the current market cap—potentially driving the SP to
$30+ (ANDA for NRX-100 submitted on June 5th).
Additionally, the NDAs for NRX-100 and NRX-101 are ready for submission, with all necessary materials in hand—making further upside a matter of timing, not feasibility.
